Venous thromboembolism (VTE) is a leading cause of complication and death for hospitalized patients. Patients who sustain a VTE have approximately twice the length of stay and total inpatient cost as patients who do not.

Prevention of hospital associated VTE (HA-VTE) is a national priority.

Introducing OsciFlex

Venous blood clots form specifically at the valves, and genetic prevention of clots at these sites requires pulses of reversing flow of blood that current mechanical therapy devices like intermittent compression and foot pumps don’t create.

Direct imaging of human blood flow in response to passive movements has identified that simultaneous foot flexion and compression at specific intervals creates optimal blood flow patterns.

About VTE

Root Cause of VTE Found

Scientists at the University of Pennsylvania have discovered a root cause of clot formation and venous thromboembolism (VTE).

The discovery revealed that recirculatory flow within the valve pockets of the legs activate a protective genetic program in the cells that line the pocket. This program stimulates the cells to alter the proteins they express to prevent clot formation.  A patient’s lack of mobility while in the hospital severely limits this protective recirculatory flow, putting the patient at increased risk for VTE.

Read more about the study and its conclusions from the Journal of Clinical Investigation.

Click here to learn more about the study.

Continue reading “About VTE”

About OsciFlex

OsciFlex LLC was founded in 2017 by John Welsh, PhD and Mark Kahn, MD at the University of Pennsylvania. Dr. Welsh and Dr. Kahn discovered the molecular pathways relating blood flow pattern to endothelial gene expression of thrombosis related proteins, outlined a protocol to analyze venous valve oscillatory flow in human subjects using vascular ultrasound, and created the initial OsciFlex device design. 

Continue reading “About OsciFlex”